comparemela.com

Latest Breaking News On - Finch therapeutics - Page 7 : comparemela.com

FDA approves Seres microbiota drug for recurrent gut infection

BioPharma

United statesPeter marksEvelo biosciencesDrug administration onMelinda gates foundationDrug administrationSeres therapeuticsBiologics evaluationFlagship pioneeringFerring pharmaceutical reybotaFinch therapeutics

$107m funding round to let Vedanta take oral microbiome therapeutic to phase 3

The microbiome therapeutic developer Vedanta Biosciences has raked in $106.5m to bankroll the launch of a phase 3 trial of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI).

Bernat olleDrug administrationDevelopment authorityUs biomedical advanced researchHealth scienceAction fundFerring pharmaceutical rebyotaSeres therapeuticsAdvanced researchMaat pharmaFinch therapeuticsBio developmentsLive biotherapeutics

Finch Therapeutics taps Matthew Blischak as CEO, appoints CFO

Incoming CEO Matthew Blischak succeeds Mark Smith, who will remain with the firm as a scientific and strategic advisor.

Susan grafLance thibaultMark smithMatthew blischakTeva pharmaceuticalsRoivant sciencesFinch therapeuticsDanforth advisors

Global Microbiome Therapeutics Markets Report, 2021-2022 & 2023-2027 Featuring Major Players Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences and Ysopia Bioscience

/PRNewswire/ The "Microbiome Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com s offering. The report provides a comprehensive.

Ysopia bioscienceLaura woodMaat pharmaEvelo biosciencesOffice hours callE st office hours callPylum biosciences incAzitra incHuman healthChain biotechnology ltdCustom researchStrategies for the development of microbiome therapeuticsIntralytix incTheriva biologics incVedanta biosciences incSenda biosciences inc

Dr Jessica Allegretti: Major Advancements Being Explored for Prevention, Treatment of CDI

Jessica Allegretti, MD, MPH, medical director of the Crohn's and Colitis Center, Brigham and Women's Hospital, reviews emerging therapeutics being investigated for the prevention and treatment of Clostridioides difficile infection (CDI).

Jessica allegrettiColitis centerSeres therapeuticsVedanta biosciencesFinch therapeuticsInfectious diseaseClostridioides difficile infection

vimarsana © 2020. All Rights Reserved.